|
|
 |
|
Viewing report
|
|
|
|
Dementia Therapy Area Pipeline Report
Life Science Analytics, March 2009, Pages: 67
Life Science Analytics, Dementia Therapy Area Pipeline Report contains detailed information on the dementia drug pipeline. This report provides insight into the pipeline status of dementia drugs by company and by stage as well as a summary of the latest news and developments in this area.
Scope of the report:
Each Life Science Analytics’ Therapy Area Pipeline Report provides the user with real detail on drug pipelines, by company and by stage, for each specific therapy area. The latest news, by company, also ensures that each report is fresh and up-to-date.
In addition to new developments and disease specific pipeline projects, each report also contains extensive information in tabular format on a company’s full product pipeline and products by phase of development with regard to the therapy area.
Full pipeline details, by stage, are provided and include detailed product descriptions, information on partnering activity plus clinical trial intelligence. Each Therapy Area Pipeline Report also provides detail on the top 20 companies with products in the early stage of development and the top 20 companies with products in the late stage of development. Finally, each report also provides a comparison with other major indications in the disease hub based on Marketed Products vs. Pipeline Products.
Key benefits
- Understand a company’s strategic position by accessing detailed independent intelligence on its product pipeline for specific therapy areas.
- Keep track of your competitors and partners by better understanding their product pipeline.
- Monitor a company’s research effectiveness by determining pipeline depth and number of products in development by clinical phase for specific disease areas.
- Maintain a critical competitive advantage.
Customers who bought this item also bought
Stakeholder Perspectives: Mild Cognitive Impairment and Dementia - Aricept in race to pioneer unexplored markets
Neuroprotection - Drugs, Markets and Companies
Mild Cognitive Impairment - Unlocking the Potential of Prodromal Alzheimer's Disease and Beyond
North America Neurology Devices Investment Opportunities, Analysis and Forecasts to 2015
Cognitive Impairment In Schizoaffective Disorder - Inevitable Or Treatable?
CNS Drug Licensing: Opportunities, Analysis, Rating and Ranking - A Worldwide Study
Psychopharmacotherapy Market Insights: Obstacles and Opportunities in Mood Disorders and Cognitive Impairment, 2005-2012
Transdermal & Transmucosal Delivery of Therapeutics, 2nd Edition
CNS European Market Competitive Strategies - Competitive Analysis, Profiles and Portfolio Strategies of the Top 20 CNS Therapeutic Manufacturers in Europe (2001 Edition)
Stakeholder Insight: Local and Locally Advanced Prostate Cancer
Pipeline Insight: Alzheimers Disease - A Busy Future, with Diagnosis, Disease Modification and Prevention Key to Growing Market
Stakeholder Insight: Prostate Cancer Treatment in the USA
|
|
|
|
